
NE 15 MB STEET



TRANSMITTAL Filling Date Interpretation Number Og/993,344 Filling Date Interpretation Number Og/993,344 Filling Date Interpretation Number Og/993,344 Filling Date Interpretation Number Ogeorge Jackowski Art Unit Examiner Name Olga N. Chernyshev Interpretation Number Olga N. Chernyshev Interpretation Number Olga N. Chernyshev Interpretation Number Interpretation Number Interpretation Number Olga N. Chernyshev Interpretation Number Interpretation Nu	antioi number.
Total Number of Pages in This Submission ENCLOSURES (Check all that apply) After Allowance Communic	1
After Allowance Communic	
	
Fee Attached Amendment/Reply After Final Aftidavits/declaration(s) Extension of Time Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts Under 37 CFR 1.52 or 1.53 Licensing-related Papers Appeal Communication to to of Appeals and Interference Appeal Communication to a (Appeal Notice, Brief, Reply English of Appeal Communication to a for Appeal Comm	C) Board es FC Brief)
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual Signature Date Ferris H. Lander McHale & Slavin, P.A. Loueled	
CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:	: postage as
Typed or printed Debra N. Gerstemerer	
Signature Date 122-20	<u>U3</u>

Inis collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

: Jackowski et al.

INVENTION

: Glycoprotein and Apolipoprotein Biopolymer Markers Indicative of

Alzheimers Disease

SERIAL NUMBER

: 09/993,344

FILING DATE

: November 23, 2001

EXAMINER

: Chernyshev, Olga N.

GROUP ART UNIT

: 1646

OUR FILE NO.

: 2132.096

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents

TO:

Mail Stop: Non-Fee Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO OFFICE COMMUNICATION OF NOVEMBER 12, 2003

Sir:

In response to the Office Communication dated November 12, 2003 having a shortened statutory period for response set to expire December 12, 2003, kindly enter the following response:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 13 of this paper.